Uropolyacitide injection

This product is an intravenous injection containing a variety of organic acids and peptides separated, extracted and purified from healthy human urine. Its mechanism of action is still unclear. The current clinical research results (two cycles of medication) show that this product combined with chemotherapy has a certain effect on non-small cell lung cancer and breast cancer, and also has a certain improvement on the quality of life of patients. The follow-up results of patients one and two years after treatment show that this product has a tendency to improve the median survival time and survival rate of patients, but it is not significant and needs further research to confirm.

This product is a sterile aqueous solution extracted and purified from human urine, containing a variety of organic acids and polypeptides with a molecular weight less than 6000D. The main ingredients are hippuric acid, phenylacetylglutamine and polypeptides.

This product is a dark brown clear liquid with a special odor.

Combined with chemotherapy, it can be used for adjuvant treatment of advanced breast cancer and non-small cell lung cancer.

Combined with chemotherapy, 300 ml each time, once a day, start administration 7 days before chemotherapy, stop using this product on the day of chemotherapy, for a total of 2 to 3 cycles. Dilute uropolyacitide with sodium chloride injection or 5% glucose injection at a ratio of 1:1 and drip intravenously (if conditions permit, try to drip subclavian vein), with a drip rate of 100 ml/hour of the original drug being appropriate.

Mainly gastrointestinal reactions, manifested as nausea, vomiting, diarrhea, poor appetite, abdominal distension, etc. Other adverse reactions are pain, dry mouth, chest discomfort, facial flushing, palpitations, etc. Most of them are grade I to II and can recover on their own. Symptomatic treatment can be given. Peripheral intravenous administration may cause venous irritation symptoms and phlebitis. Venous irritation is significantly reduced when subclavian vein drip is used.

Use with caution in patients with extreme physical exhaustion.

Precautions for children: Not yet clear. Precautions for pregnancy and lactation: Not yet clear. Precautions for the elderly: Not yet clear.

Not yet clear.

Sealed and stored at 2-8°C. Tentatively 18 months.

100 ml

18 months